S&P Futures
5,954.00 -4.25 (-0.07%) Dow Futures
43,909.00 +8.00 (+0.02%) Nasdaq Futures
20,880.00 -14.00 (-0.07%) Russell 2000 Futures
2,401.80 -4.00 (-0.17%) Crude Oil
71.93 +0.24 (+0.33%) Gold
2,654.60 -21.70 (-0.81%)
Plus Therapeutics, Inc. (PSTV)
After hours:
| Previous Close | 1.3600 |
| Open | 1.2500 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 1.1700 - 1.4900 |
| 52 Week Range | 1.1500 - 2.7800 |
| Volume | |
| Avg. Volume | 53,442 |
| Market Cap | 8.432M |
| Beta (5Y Monthly) | 0.67 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.2000 |
| Earnings Date | Nov 14, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 26.00 |
GlobeNewswirePlus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership
Partnership will expand Plus’ capability to meet late-stage clinical and commercial forecasts for Rhenium (186Re) Obisbemeda and reinforce supply chain redundancyAUSTIN, Texas and INDIANAPOLIS, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing targeted radiotherapeutics for central nervous system (CNS) cancers, and SpectronRx, a leading radiopharmaceutical contract developer and manufacturer, announced the signing of a Ma
- GlobeNewswire
Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024
AUSTIN, Texas, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company will report third quarter 2024 financial results on Thursday, November 14, 2024, after market close. Plus Therapeutics’ management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the
